EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Haemate P) in von Willebrand Disease: A Systematic Review and Pharmacovigilance Update

Carmen Escuriola Ettingshausen iD, Riitta Lassila iD, Gines Escolar iD, Christoph Male iD, Kathrin Schirner iD, Lisa Heyder iD, Erik Berntorp iD

Haemophilia · 2025

DOI: 10.1111/hae.15138 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Haemophilia, 2025. Verfasst von Carmen Escuriola Ettingshausen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Haemophilia Centre Rhein Main (HZRM), Frankfurt/Main, Germany. Hauptthemen laut MEDLINE: von Willebrand Diseases, Factor VIII, von Willebrand Factor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSL Behring.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Von Willebrand disease (VWD) is an inherited bleeding disorder caused by deficient or dysfunctional von Willebrand factor (VWF). VWF replacement therapy is indicated in VWD management.

Methods

This systematic review was conducted to evaluate all available evidence of the efficacy, safety, dosing and consumption of pasteurized plasma‐derived human coagulation FVIII/human VWF (pdVWF/FVIII; Haemate P/Humate‐P) concentrate for on‐demand (OD) treatment, surgical prophylaxis and long‐term prophylaxis of patients with VWD. A systematic search was performed in MEDLINE and Cochrane Library databases to identify studies (7 June 1982–31 May 2023) reporting the use of pdVWF/FVIII in VWD according to predefined selection criteria. Pharmacovigilance data were also retrieved for the same period.

Results

Fifteen studies were identified, 12 being observational and three interventional. Efficacy and safety assessments and treatment protocols varied across the studies which hindered direct comparisons. Haemostatic efficacy of pdVWF/FVIII was rated excellent/good for OD treatment in 95%–98% of bleeds and in 94%–100% of surgeries. In two separate studies, prophylactic efficacy was rated excellent/good in 100% of treatment cycles. Where reported, median annualized bleeding rates decreased from 3–24 prior prophylaxis to 0.5–6 during prophylaxis. Analysis of pharmacovigilance safety reports showed that pdVWF/FVIII was associated with a low rate of adverse events.

Conclusions

This systematic literature review and analysis of pharmacovigilance data summarize evidence of over 40 years of clinical use of pdVWF/FVIII, supporting its safety and efficacy in VWD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Willebrand DiseasesFactor VIIIvon Willebrand FactorHumansPharmacovigilanceHemorrhageDrug Combinations

Stichwörter der Autor:innen

factor VIIIsafetysystematic reviewvon Willebrand diseasevon Willebrand factor

Substanzen

Factor VIIIvon Willebrand Factorfactor VIII, von Willebrand factor drug combinationDrug Combinations

Autor:innen und Institutionen

  • Haemophilia Centre Rhein Main (HZRM), Frankfurt/Main, Germany.
  • Department of Haematology, Helsinki University Hospital, Coagulation Disorders Unit, Comprehensive Cancer Centre, and Research Program Unit in System Oncology, University of Helsinki, Helsinki, Finland.
  • Department of Pathology, Hematopathology, Centre de Diagnostic Biomedic (CDB), Hospital Clinic de Barcelona, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
  • Department of Paediatrics, Medical University of Vienna, Vienna, Austria.
  • CSL Innovation GmbH, Marburg, Germany.
  • Department of Translational Medicine, Clinical Coagulation Research Unit, Lund University, Malmö, Sweden.

ORCID-Profile: Carmen Escuriola Ettingshausen, Riitta Lassila, Gines Escolar, Christoph Male, Kathrin Schirner, Lisa Heyder, Erik Berntorp

Förderung

  • CSL Behring

Zitieren

APA

Ettingshausen, C. E., Lassila, R., Escolar, G., Male, C., Schirner, K., Heyder, L., & Berntorp, E. (2025). Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Haemate P) in von Willebrand Disease: A Systematic Review and Pharmacovigilance Update. Haemophilia. https://doi.org/10.1111/hae.15138

Vancouver

Ettingshausen CE, Lassila R, Escolar G, Male C, Schirner K, Heyder L, et al. Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Haemate P) in von Willebrand Disease: A Systematic Review and Pharmacovigilance Update. Haemophilia. 2025. doi:10.1111/hae.15138

BibTeX
@article{Ettingshausen2025,
  author = {Ettingshausen, Carmen Escuriola and Lassila, Riitta and Escolar, Gines and Male, Christoph and Schirner, Kathrin and Heyder, Lisa and Berntorp, Erik},
  title = {Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Haemate P) in von Willebrand Disease: A Systematic Review and Pharmacovigilance Update},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.15138}
}
Kostenlos starten →